Journal Mobile Options
Table of Contents
Vol. 27, No. 2, 2009
Issue release date: March 2009
Dement Geriatr Cogn Disord 2009;27:194–200
(DOI:10.1159/000203130)

Biomarkers in Relation to Cognitive Reserve in Patients with Mild Cognitive Impairment – Proof of Concept

Rolstad S. · Nordlund A. · Eckerström C. · Gustavsson M.H. · Zetterberg H. · Wallin A.
Institute of Neuroscience and Physiology, Sahlgrenska Academy at Göteborg University, Mölndal, Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The concept of the cognitive reserve (CR) posits that factors such as education enable compensation for the effect of brain pathology. Consequently, pathology should be more pronounced in individuals with higher CR before becoming clinically apparent. Biomarkers such as total tau (t-tau) and β-amyloid 42 (Aβ42) may be surrogates for pathology in relation to CR in patients with neurodegenerative disease. Objective: To examine the applicability of biomarkers as surrogates for pathology in relation to the CR in patients with mild cognitive impairment (MCI) either converting to dementia or remaining stable at follow-up. Method: Comparisons of baseline t-tau, Aβ42, educational years and global cognition for MCI patients either converting to dementia (n = 57) or remaining stable (n = 91) were made. Patients converting to dementia were grouped on the basis of educational level and compared considering biomarkers and neuropsychological tests. Results: Stable MCI patients were better educated, performed better cognitively, had higher Aβ42 levels and lower levels of t-tau. Converting MCI patients with higher education had lower levels of Aβ42 and performed equally in neuropsychological tests compared to those with lower education. Conclusion: Our results suggest that highly educated MCI patients subsequently converting to dementia display more amyloid pathology.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Stern Y: What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448–460.
  2. Katzman R, Aronson M, Fuld P, Kawas C, Brown T, Morgenstern H, Frishman W, Gidez L, Eder H, Ooi WL: Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol 1989;25:317–324.
  3. Stern Y: Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:S69–S74.
  4. The Canadian Study of Health and Aging: Risk factors for Alzheimer’s disease in Canada. Neurology 1994;44:2073–2080.
  5. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, Brayne C, Copeland JR, Dartigues JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A: Rates and risk factors for dementia and Alzheimer’s disease: results from Eurodem pooled analyses. Eurodem incidence research group and work groups. European studies of dementia. Neurology 1999;52:78–84.
  6. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R: Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA 1994;271:1004–1010.
  7. Albert MS, Jones K, Savage CR, Berkman L, Seeman T, Blazer D, Rowe JW: Predictors of cognitive change in older persons: MacArthur studies of successful aging. Psychol Aging 1995;10:578–589.
  8. Amieva H, Jacqmin-Gadda H, Orgogozo JM, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues JF: The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005;128:1093–1101.
  9. Scarmeas N, Albert SM, Manly JJ, Stern Y: Education and rates of cognitive decline in incident Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006;77:308–316.
  10. Stern Y, Alexander GE, Prohovnik I, Mayeux R: Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer’s disease. Ann Neurol 1992;32:371–375.
  11. Alexander GE, Furey ML, Grady CL, Pietrini P, Brady DR, Mentis MJ, Schapiro MB: Association of premorbid intellectual function with cerebral metabolism in Alzheimer’s disease: implications for the cognitive reserve hypothesis. Am J Psychiatry 1997;154:165–172.
  12. Scarmeas N, Zarahn E, Anderson KE, Habeck CG, Hilton J, Flynn J, Marder KS, Bell KL, Sackeim HA, Van Heertum RL, Moeller JR, Stern Y: Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol 2003;60:359–365.
  13. Stern Y, Alexander GE, Prohovnik I, Stricks L, Link B, Lennon MC, Mayeux R: Relationship between lifetime occupation and parietal flow: implications for a reserve against Alzheimer’s disease pathology. Neurology 1995;45:55–60.
  14. Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE: Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer’s disease. J Neurosci 2003;23:986–993.
  15. Kemppainen NM, Aalto S, Karrasch M, Nagren K, Savisto N, Oikonen V, Viitanen M, Parkkola R, Rinne JO: Cognitive reserve hypothesis: Pittsburgh compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer’s disease. Ann Neurol 2008;63:112– 118.
  16. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE: Education modifies the association of amyloid but not tangles with cognitive function. Neurology 2005;65:953–955.
  17. Boyle PA, Wilson RS, Schneider JA, Bienias JL, Bennett DA: Processing resources reduce the effect of Alzheimer pathology on other cognitive systems. Neurology 2008;70:1534–1542.
  18. Blennow K: CSF biomarkers for mild cognitive impairment. J Intern Med 2004;256:224–234.
  19. Blennow K: Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. Neuro Rx 2004;1:213–225.
  20. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.
  21. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, De Carli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–246.
  22. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A: The Goteborg MCI Study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005;76:1485–1490.
  23. Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M: Stepwise comparative status analysis (STEP): a tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol 1996;9:185–199.
  24. Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 1992;40:1221–1226.
  25. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  26. Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997;9(suppl 1):173–176, discussion 177–178.
  27. Rolstad S, Nordlund A, Gustavsson MH, Eckerström C, Klang O, Hansen S, Wallin A: The Swedish National Adult Reading Test (NART-swe): a test of premorbid IQ. Scand J Psychol 2008;49:577–582.
  28. Rentz DM, Huh TJ, Faust RR, Budson AE, Scinto LF, Sperling RA, Daffner KR: Use of IQ-adjusted norms to predict progressive cognitive decline in highly intelligent older individuals. Neuropsychology 2004;18:38–49.
  29. AAN: Assessment: neuropsychological testing of adults – considerations for neurologists. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 1996;47:592–599.
  30. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231–245.
  31. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673–680.
  32. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–746.
  33. Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Hansen S, Wallin A: Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI. J Int Neuropsychol Soc 2008;14:582–590.
  34. Albert SM, Teresi JA: Reading ability, education, and cognitive status assessment among older adults in Harlem, New York City. Am J Public Health 1999;89:95–97.
  35. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373–379.
  36. Mayeux R: Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26:81–104.
  37. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A: Intra-individual stability of CSF biomarkers for Alzheimer’s disease over two years. J Alzheimers Dis 2007;12:255–260.
  38. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP: No association of CSF biomarkers with apoeepsilon4, plaque and tangle burden in definite Alzheimer’s disease. Brain 2007;130:2320–2326.
  39. Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H.: Aspects of beta-amyloid as a biomarker for Alzheimer’s disease. Biomarkers Med 2007;1:59–78.
  40. Strozyk D, Blennow K, White LR, Launer LJ: CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652–656.
  41. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512–519.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50